# Medical Radiological Research Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/medical-radiological-research-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 50 |
| Citations | 91,341 |
| City | Obninsk |
| Country | RU |
| Description | Medical Radiological Research Center is a research organisation in Obninsk, RU. OpenAlex records 2,728 works and 91,341 citations for it. 1,368 researchers list it as their most recent affiliation. |
| Homepage | http://mrrc-obninsk.ru/en/ |
| OpenAlex ID | https://openalex.org/I4210117327 |
| Researchers | 1,368 |
| ROR ID | https://ror.org/02dr19631 |
| Type | facility |
| Works | 2,728 |

## University papers

- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/abiraterone-plus-prednisone-in-metastatic-castration-sensitive-prostate-cancer/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/abiraterone-acetate-plus-prednisone-in-patients-with-newly-diagnosed-high-risk/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-in-patients-with/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)

## University top topics

Showing 8 of 24.

- [Effects of Radiation Exposure](https://scholariq.org/topics/effects-of-radiation-exposure/)
- [Radiation Dose and Imaging](https://scholariq.org/topics/radiation-dose-and-imaging/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Nuclear Physics and Applications](https://scholariq.org/topics/nuclear-physics-and-applications/)
- [Radioactivity and Radon Measurements](https://scholariq.org/topics/radioactivity-and-radon-measurements/)
- [Radiation Therapy and Dosimetry](https://scholariq.org/topics/radiation-therapy-and-dosimetry/)
- [Thyroid Cancer Diagnosis and Treatment](https://scholariq.org/topics/thyroid-cancer-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.